PTC
ARQT icon

Private Trust Company’s Arcutis Biotherapeutics ARQT Stock Holding History

Private Trust Company’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-215
Closed -$1.14K – 2305
2023
Q3 		$1.14K Hold
215
– – ﹤0.01% 2192
2023
Q2 		$2.05K Buy
215
+25
+13% +$277 ﹤0.01% 2109
2023
Q1 		$2.09K Buy
190
+30
+19% +$434 ﹤0.01% 2076
2022
Q4 		$2K Buy
160
+50
+45% +$874 ﹤0.01% 1989
2022
Q3 		$2K Buy
110
+45
+69% +$1.02K ﹤0.01% 1853
2022
Q2 		$1K Buy
+65
New +$1.33K ﹤0.01% 2011

Other funds holding ARQT

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Private Trust Company's ARQT Position: Q4 2023 in Review

Private Trust Company sold out of Arcutis Biotherapeutics (ARQT) in Q4 2023, closing a stake of 215 shares — an estimated $1.14K sold.

Private Trust Company first reported a position in ARQT in Q2 2022 and held it in 6 quarters. The position peaked at $2.09K in Q1 2023. 133 funds tracked by Wall St. Rank hold ARQT as of Q4 2023.

  • Private Trust Company reported no remaining Arcutis Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • Private Trust Company sold 215 Arcutis Biotherapeutics shares in Q4 2023, an estimated $1.14K.
  • Private Trust Company first reported a position in Arcutis Biotherapeutics in Q2 2022 and held it in 6 quarters.
  • Private Trust Company's Arcutis Biotherapeutics position peaked at $2.09K in Q1 2023.
  • 133 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2023.

Based on Private Trust Company's 13F filing for Q4 2023, filed 24 Jan 2024.